Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Variation in collagenase Clostridium histolyticum practice patterns: a Survey of ISSM Members

Abstract

Collagenase clostridium histolyticum (CCH, Xiaflex, Xiapex) is the only FDA-approved medication for treatment of Peyronie’s disease. It is unclear how practitioners actually use CCH in their own practices. The objectives of the study were: (1) to identify variability in practice patterns for CCH among practitioners, (2) to assess adherence to the package insert instructions, and (3) to evaluate whether provider satisfaction was associated with adherence to instructions. A 30-question online survey was distributed to 1270 members of the International Society for Sexual Medicine (ISSM) from the EU, USA, Canada and Australia. Of the 30 questions, 10 survey questions had only one response consistent with the CCH package insert recommendations. An “adherence” score was calculated for each survey participant depending on how many of these questions were answered correctly. The average adherence scores of various groups were compared using a student’s t-test. A chi-squared test was used to determine association between categorical variables. Of 202 total responses, 132 practitioners reported using CCH out of 1270 ISSM members from countries where CCH is available (10.4% response rate). Practitioners from outside the USA were more likely to be satisfied with CCH (p = 0.006), and more experienced users (>20 uses) were more likely to be satisfied than less experienced users (<10 uses) (p = 0.046). Satisfied users of CCH did not have significantly different adherence scores than non-satisfied users. Even though 67% of practitioners believed they followed the package insert guidelines, only 11% adhered to all the recommendations evaluated by the survey. Treatment adherence to package insert guidelines does not appear to be associated with provider satisfaction. We believe there is utility in seeing a snapshot of these practice patterns so practitioners may feel more comfortable adapting their own practice in light of newer data supporting alternative administration methods.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Similar content being viewed by others

References

  1. Ralph D, Gonzalez-Cadavid N, Milrone V, Perovic S, Sohn M, Usta M, et al. The management of Peyronie’s disease: evidence-based 2010 guidelines. J Sex Med. 2010;7:2359–74.

    Article  Google Scholar 

  2. Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, et al. Peyronie’s disease: AUA guideline. J Urol. 2015;194:745–53.

    Article  Google Scholar 

  3. Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199–207.

    Article  CAS  Google Scholar 

  4. Highlights of Prescribing Information [Internet]. Endo Pharmaceuticals, Inc.; 2018. http://www.endo.com/File.Library/Products/Prescribing.Information/Xiaflex_prescribing_information.html. Accessed 13 Dec 2018.

  5. Nguyen HMT, Anaissie J, DeLay KJ, Yafi FA, Sikka SC, Hellstrom WJG. Safety and efficacy of collagenase Clostridium histolyticum in the treatment of acute-phase Peyronie’s disease. J Sex Med. 2017;14:1220–5.

    Article  Google Scholar 

  6. Hellstrom WJG, Tan RBW, Liu G. Safety profile of collagenase Clostridium histolyticum stratified by degree of penile curvature in patients with Peyronie disease. Urology. 2017;106:237 e9–237 e14.

    Article  Google Scholar 

  7. Cocci A, Russo GI, Salonia A, Cito G, Regis F, Polloni G, et al. Predictive factors of patients’ and their partners’ sexual function improvement after collagenase Clostridium histolyticum injection for Peyronie’s disease: results from a Multi-Center Single-Arm Study. J Sex Med. 2018;15:716–21.

    Article  Google Scholar 

  8. Abdel Raheem A, Capece M, Kalejaiye O, Abdel-Raheem T, Falcone M, Johnson M, et al. Safety and effectiveness of collagenase Clostridium histolyticum in the treatment of Peyronie’s disease using a new modified shortened protocol. BJU Int. 2017;120:717–23.

    Article  CAS  Google Scholar 

  9. Chong W, Tan RB. Injectable therapy for Peyronie’s disease. Transl Androl Urol. 2016;5:310–7.

    Article  Google Scholar 

  10. Gabrielson AT, Spitz JT, Hellstrom WJG. Collagenase lostridium histolyticum in the treatment of urologic disease: current and future impact. Sex Med Rev. 2018;6:143–56.

    Article  Google Scholar 

  11. Wymer K, Zielgelmann M, Savage J, Kohler T, Trost L. Plaque calcification: an important predictor of collagenase lostridium histolyticum treatment outcomes for men with Peyronie’s disease. Urology. 2018;119:109–14.

    Article  Google Scholar 

  12. Yafi FA, Anaissie J, Zurawin J, Sikka S, Hellstrom WJG. Results of SMSNA Survey regarding complications following intralesional injection thearpy with collagenase Clostridium histolyticum for Peyronie’s disease. J Sex Med. 2016;13:684–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R. Ramasamy.

Ethics declarations

Conflict of interest

Dr. Ramasamy has previously received a research grant from Endo Pharmaceuticals which was unrelated to this study. Dr. Pastuszak is a consultant/speaker for Endo Pharmaceuticals. The remaining authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Masterson, T.A., Galante, A., Butaney, M. et al. Variation in collagenase Clostridium histolyticum practice patterns: a Survey of ISSM Members. Int J Impot Res 31, 439–443 (2019). https://doi.org/10.1038/s41443-019-0126-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41443-019-0126-y

This article is cited by

Search

Quick links